<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35575095</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1558-8238</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>132</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>16</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical investigation</Title>
          <ISOAbbreviation>J Clin Invest</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Benefits of aerobic exercise in myotonic dystrophy type 1.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e160229</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI160229</ELocationID>
        <Abstract>
          <AbstractText>Myotonic dystrophy type 1 (DM1) is a multisystem trinucleotide repeat expansion disorder characterized by the misregulated alternative splicing of critical mRNAs. Previous work in a transgenic mouse model indicated that aerobic exercise effectively improves splicing regulation and function in skeletal muscle. In this issue of the JCI, Mikhail et al. describe the safety and benefits of applying this approach in individuals affected by DM1. A 12-week aerobic exercise program improved aerobic capacity and mobility, but not by the mechanism observed in transgenic mice. Here, we consider the possible reasons for this disparity and review other salient findings of the study in the context of evolving DM1 research.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mackenzie</LastName>
            <ForeName>Samuel J</ForeName>
            <Initials>SJ</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamel</LastName>
            <ForeName>Johanna</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thornton</LastName>
            <ForeName>Charles A</ForeName>
            <Initials>CA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Invest</MedlineTA>
        <NlmUniqueID>7802877</NlmUniqueID>
        <ISSNLinking>0021-9738</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>Aerobic exercise elicits clinical adaptations in myotonic dystrophy type 1 patients independently of pathophysiological changes﻿</RefSource>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017398" MajorTopicYN="N">Alternative Splicing</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009223" MajorTopicYN="Y">Myotonic Dystrophy</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012326" MajorTopicYN="N">RNA Splicing</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Conflict of interest:</b> CAT serves as a board member of the Myotonic Dystrophy Foundation, receives compensation for serving on the scientific advisory boards of Dyne Therapeutics and Pepgen, receives research funding from Ionis Pharmaceuticals and Dyne Therapeutics, and receives licensing royalties through the University of Rochester. CAT is coinventor on the following patents: “Compositions and methods related to protein displacement therapy for myotonic dystrophy” (US9371527B2); “Methods and compositions for treatment of myotonia” (US7964570B2); “Modulation of dystrophia myotonica-protein kinase (DMPK) expression” (US9765338B2).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35575095</ArticleId>
        <ArticleId IdType="pmc">PMC9106338</ArticleId>
        <ArticleId IdType="doi">10.1172/JCI160229</ArticleId>
        <ArticleId IdType="pii">160229</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Florence JM, et al.  Activity, creatine kinase, and myoglobin in Duchenne muscular dystrophy: a clue to etiology? Neurology. 1985;35(5):758–761. doi: 10.1212/WNL.35.5.758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.35.5.758</ArticleId>
            <ArticleId IdType="pubmed">4039424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webster C, et al.  Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell. 1988;52(4):503–513. doi: 10.1016/0092-8674(88)90463-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(88)90463-1</ArticleId>
            <ArticleId IdType="pubmed">3342447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lott DJ, et al.  Safety, feasibility, and efficacy of strengthening exercise in Duchenne muscular dystrophy. Muscle Nerve. 2021;63(3):320–326. doi: 10.1002/mus.27137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.27137</ArticleId>
            <ArticleId IdType="pubmed">33295018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spaulding HR, Selsby JT. Is exercise the right medicine for dystrophic muscle? Med Sci Sports Exerc. 2018;50(9):1723–1732. doi: 10.1249/MSS.0000000000001639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1249/MSS.0000000000001639</ArticleId>
            <ArticleId IdType="pubmed">29649068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller JW, et al.  Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000;19(17):4439–4448. doi: 10.1093/emboj/19.17.4439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/19.17.4439</ArticleId>
            <ArticleId IdType="pmc">PMC302046</ArticleId>
            <ArticleId IdType="pubmed">10970838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mankodi A, et al.  Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet. 2001;10(19):2165–2170. doi: 10.1093/hmg/10.19.2165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/10.19.2165</ArticleId>
            <ArticleId IdType="pubmed">11590133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wagner SD, et al.  Dose-dependent regulation of alternative splicing by MBNL proteins reveals biomarkers for myotonic dystrophy. PLoS Genet. 2016;12(9):e1006316.  doi: 10.1371/journal.pgen.1006316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pgen.1006316</ArticleId>
            <ArticleId IdType="pmc">PMC5082313</ArticleId>
            <ArticleId IdType="pubmed">27681373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang H, et al.  Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet. 2004;13(24):3079–3088. doi: 10.1093/hmg/ddh327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddh327</ArticleId>
            <ArticleId IdType="pubmed">15496431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mankodi A, et al.  Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res. 2005;97(11):1152–1155. doi: 10.1161/01.RES.0000193598.89753.e3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.RES.0000193598.89753.e3</ArticleId>
            <ArticleId IdType="pubmed">16254211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharp L, et al.  Endurance exercise leads to beneficial molecular and physiological effects in a mouse model of myotonic dystrophy type 1. Muscle Nerve. 2019;60(6):779–789. doi: 10.1002/mus.26709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.26709</ArticleId>
            <ArticleId IdType="pmc">PMC7026901</ArticleId>
            <ArticleId IdType="pubmed">31509256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manta A, et al.  Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice. J Physiol. 2019;597(5):1361–1381. doi: 10.1113/JP277123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/JP277123</ArticleId>
            <ArticleId IdType="pmc">PMC6395422</ArticleId>
            <ArticleId IdType="pubmed">30628727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ravel-Chapuis A, et al.  Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles. Hum Mol Genet. 2018;27(19):3361–3376. doi: 10.1093/hmg/ddy245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddy245</ArticleId>
            <ArticleId IdType="pmc">PMC6140770</ArticleId>
            <ArticleId IdType="pubmed">29982462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu N, et al.  Antisense oligonucleotide and adjuvant exercise therapy reverse fatigue in old mice with myotonic dystrophy. Mol Ther Nucleic Acids. 2021;23:393–405. doi: 10.1016/j.omtn.2020.11.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.omtn.2020.11.014</ArticleId>
            <ArticleId IdType="pmc">PMC7787993</ArticleId>
            <ArticleId IdType="pubmed">33473325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mikhail AI, et al.  Aerobic exercise elicits clinical adaptations in myotonic dystrophy type 1 patients independently of pathophysiological changes. J Clin Invest. 2022;132(10):e156125 </Citation>
        </Reference>
        <Reference>
          <Citation>Mankodi A, et al.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science. 2000;289(5485):1769–1773. doi: 10.1126/science.289.5485.1769.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.289.5485.1769</ArticleId>
            <ArticleId IdType="pubmed">10976074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wheeler TM, et al.  Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science. 2009;325(5938):336–339. doi: 10.1126/science.1173110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1173110</ArticleId>
            <ArticleId IdType="pmc">PMC4109973</ArticleId>
            <ArticleId IdType="pubmed">19608921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnes PR, et al.  Skeletal muscle metabolism in myotonic dystrophy A 31P magnetic resonance spectroscopy study. Brain. 1997;120(pt 10):1699–1711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9365364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gramegna LL, et al.  Mitochondrial dysfunction in myotonic dystrophy type 1. Neuromuscul Disord. 2018;28(2):144–149. doi: 10.1016/j.nmd.2017.10.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2017.10.007</ArticleId>
            <ArticleId IdType="pubmed">29289451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiss T. Small nucleolar RNAs: an abundant group of noncoding RNAs with diverse cellular functions. Cell. 2002;109(2):145–148. doi: 10.1016/S0092-8674(02)00718-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(02)00718-3</ArticleId>
            <ArticleId IdType="pubmed">12007400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wajahat M, et al.  Emerging functions for snoRNAs and snoRNA-derived fragments. Int J Mol Sci. 2021;22(19):10193.  doi: 10.3390/ijms221910193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms221910193</ArticleId>
            <ArticleId IdType="pmc">PMC8508363</ArticleId>
            <ArticleId IdType="pubmed">34638533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roussel MP, et al.  What is known about the effects of exercise or training to reduce skeletal muscle impairments of patients with myotonic dystrophy type 1? A scoping review. BMC Musculoskelet Disord. 2019;20(1):101.  doi: 10.1186/s12891-019-2458-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12891-019-2458-7</ArticleId>
            <ArticleId IdType="pmc">PMC6402179</ArticleId>
            <ArticleId IdType="pubmed">30836978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okkersen K, et al.  Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial. Lancet Neurol. 2018;17(8):671–680. doi: 10.1016/S1474-4422(18)30203-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(18)30203-5</ArticleId>
            <ArticleId IdType="pubmed">29934199</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
